P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Autor: Kilickap, S., Demirci, U., Bugdayci, F., Tural, D., Korkmaz, T., Paydas, S., Yilmaz, C., Turna, H., Sezer, A., Cinkir, H. Yesil, Okutur, K., Erman, M., Eralp, Y., Cabuk, D., Isikdogan, A., Demirkazik, A., Karaoglu, A., Yazilitas, D., Senler, F. Cay, Yumuk, P.F., Coskun, H., Yildiz, I., Oztop, I., Beypinar, I., Aydin, K., Kaplan, M., Meydan, N., Olmez, O.F., Ozyilkan, O., Seber, S., Arslan, C., Sendur, M.A., Cicin, I.
Zdroj: In Journal of Thoracic Oncology October 2019 14(10) Supplement:S558-S559
Databáze: ScienceDirect